重组人 B7-H3 蛋白 (ECD, His Tag), HPLC-verified

Recombinant Human B7‑H3 / CD276 Protein (ECD,His Tag)

Cat No: 11188‑H08H｜Official product page:        https://cn.sinobiological.com/recombinant-proteins/human-b7-h3-11188-h08h

Specifications

Alternate Names

Background

B7‑H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co‑inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T‑cell responses in various experimental systems. B7‑H3 may play an important role in muscle‑immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7‑H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin‑V‑like and immunoglobulin‑C‑like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor‑infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno‑inhibitory role in ovarian cancer prognosis. Recently, B7‑H3 expression has been reported in several human cancers indicating an additional function of B7‑H3 as a regulator of antitumor immunity.

北京义翘神州科技股份有限公司作为国家高新技术企业，主要从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务，同时也为制药公司或者生物技术公司提供单克隆抗体候选药物的临床前规模生产服务。义翘神州拥有多项先进的核心技术以及从研发生产到放大生产的技术平台，为重组蛋白或者抗体试剂的高通量、高效率研发生产提供保障，旨在为全球制药企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。 北京义翘神州是入选科技部"现代服务创新发展示范企业"的唯一的一家生物技术企业，是北京市民营企业科技创新百强，获批北京市单克隆抗体技术重点实验室，多次承担国家科技部重大新药创制专项、863科技攻关项目和北京市科委项目。